Unusually Long Survival (More Than Five Years to More Than 31 Years) in Twelve Patients with Relapsed Medulloblastoma Treated with Antineoplastons in Phase II Studies. CLINICMED [Internet]. 2015 Oct. 17 [cited 2025 Oct. 27];6(4):1-8. Available from: https://www.ej-clinicmed.org/index.php/clinicmed/article/view/389